Patient's Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease

被引:26
作者
Baars, Judith E. [1 ]
Siegel, Corey A. [3 ]
Kuipers, Ernst J. [1 ,2 ]
van der Woude, C. Janneke [1 ]
机构
[1] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[3] Dartmouth Hitchcock Med Ctr, Dept Gastroenterol & Hepatol, Lebanon, NH 03766 USA
关键词
Inflammatory bowel disease; Patients' perspectives; Infliximab; CROHNS-DISEASE; MAINTENANCE THERAPY; RANDOMIZED-TRIAL; INFLIXIMAB; BENEFITS; RISKS;
D O I
10.1159/000203638
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim: We hypothesized that limited information is given to patients on the risks and benefits of individual therapy, and feedback is lacking to verify if patients correctly interpreted the given information. We assessed the perspectives of patients with inflammatory bowel disease (IBD) concerning the treatment-associated risks/benefits of infliximab. Methods: Patients were asked to complete a survey regarding the benefits and risks of infliximab. Results are reported as descriptive statistics. Comparisons between groups were analyzed using independent t tests and the Kruskal-Wallis test. Results: In total, 152 IBD patients completed the questionnaire. Fifty-seven percent (78/138) estimated the 1-year remission rate from infliximab to be > 50%. Seventy-one percent (104/146) indicated they would not take a drug with risks reflecting those estimated for infliximab if the 1-year remission rate was < 75%. Crohn's disease patients and those recalling a discussion regarding the risks/benefits of infliximab treatment had higher estimates of the 1-year remission rate with infliximab than ulcerative colitis patients (p = 0.03) and patients who did not recall previous information (p = 0.03). Perceptions were independent of age and disease duration. Conclusion: IBD patients misperceive the risks and benefits of infliximab. The majority of patients would not accept treatment-related risks if the 1-year remission rate was < 75%. Counseling on treatment-associated risks and benefits should be ameliorated. Copyright (c) 2009 S. Karger AG, Basel
引用
收藏
页码:30 / 35
页数:6
相关论文
共 50 条
[41]   Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease [J].
Aardoom, Martine A. ;
Jongsma, Maria M. E. ;
de Vries, Annick ;
Wolthoorn, Jasja ;
de Ridder, Lissy ;
Escher, Johanna C. .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (04) :501-507
[42]   Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy [J].
Patel, Nisha B. ;
Vinsard, Daniela Guerrero ;
Kattah, Andrea G. ;
Kane, Sunanda V. .
DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (09) :3557-3561
[43]   Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease [J].
Ioannis Androulakis ;
Christos Zavos ;
Panagiotis Christopoulos ;
George Mastorakos ;
Maria Gazouli .
World Journal of Gastroenterology, 2015, 21 (47) :13205-13211
[44]   Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients [J].
P. Andrade ;
S. Lopes ;
R. Gaspar ;
A. Nunes ;
S. Magina ;
G. Macedo .
Digestive Diseases and Sciences, 2018, 63 :746-754
[45]   Tacrolimus Salvage in Anti-Tumor Necrosis Factor Antibody Treatment-Refractory Crohn's Disease [J].
Gerich, Mark E. ;
Pardi, Darrell S. ;
Bruining, David H. ;
Kammer, Patricia P. ;
Becker, Brenda D. ;
Tremaine, William T. .
INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) :1107-1111
[46]   Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease [J].
Bressler, Brian ;
Siegel, Corey A. .
GASTROENTEROLOGY, 2014, 146 (04) :884-886
[47]   Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy [J].
Sherman, Michael ;
Tsynman, Donald N. ;
Kim, Albert ;
Arora, Jyoti ;
Pietras, Timothy ;
Messing, Susan ;
St Hilaire, Lydia ;
Yoon, Sonia ;
Decross, Arthur ;
Shah, Ashok ;
Saubermann, Lawrence .
JOURNAL OF DIGESTIVE DISEASES, 2014, 15 (04) :174-179
[48]   The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn's Disease [J].
Alourfi, Mansour ;
Mosli, Mahmoud ;
Saadah, Omar, I .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
[49]   The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies [J].
Rubin, David T. ;
Griffith, Jenny ;
Zhang, Qisu ;
Hepp, Zsolt ;
Keshishian, Allison .
INFLAMMATORY BOWEL DISEASES, 2021, 27 (08) :1201-1209
[50]   Do Not Assume Symptoms Indicate Failure of Anti-Tumor Necrosis Factor Therapy in Crohn's Disease [J].
Bruining, David H. ;
Sandborn, William J. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (05) :395-399